Financial Performance Highlights

  • Revenue: Increased by 27% year-on-year to ₹158.3 crores in Q1 FY27 from ₹124.9 crores in Q1 FY26
  • EBITDA: Grew by 25% year-on-year to ₹54.9 crores from ₹43.9 crores
  • EBITDA Margin: Remained resilient at 34.7%
  • Profit After Tax (PAT): Increased to ₹40.6 crores compared to ₹31.3 crores in the corresponding quarter last year
  • PAT Margin: Improved to 25.6% from 25%

Business Segment Performance

Pharma, Food & Nutrition (PFN) Segment:

  • Accounted for 69% of Q1 FY27 revenue (vs. 66% in Q1 FY26)
  • Delivered 31% year-on-year growth
  • Growth predominantly volume-driven with approximately 3% from currency changes
  • Strong demand across both phosphate and Absorbis Bisglycinates portfolios
  • Customer demand for phosphate portfolio exceeds current manufacturing capacity
  • Absorbis Bisglycinates sales in Q1 have already surpassed total sales achieved during entire previous financial year

Specialty Ingredients Business:

  • Contributed 31% of revenue
  • Delivered 19% year-on-year growth
  • Margin at 26% (inclusive of NSS performance)
  • Core specialty business without NSS maintained mid-30s margin profile
  • Temporary operational constraints due to LPG supply shortage during April and first half of May affected utilization levels

Operational Challenges

  • Geopolitical uncertainties and intermittent gas supply constraints
  • Elevated logistics costs and continued supply chain disruption
  • Sharp increase in sulfur prices resulted in phosphoric acid price increasing by approximately 50% during the quarter
  • LPG supply shortage affected specialty ingredients segment operations in April and first half of May

Strategic Initiatives and Expansion Projects

Greenfield Facility in Navsari:

  • Currently undergoing regulatory approvals
  • Facility approved to supply into food and nutrition category
  • FDA approval expected in current quarter (Q2 FY27)
  • Five food nutra customers currently approving the facility (three from India, two global MNCs)
  • Supplies expected to start from this facility in Q3 FY27

Sudeep Advanced Materials (Battery Materials Venture):

  • Construction on schedule, targeting Phase 1 commissioning by April 2027
  • Deliveries of all major long-lead equipment expected to be completed in October 2026
  • 21 customers at laboratory validation stage
  • 16 customers progressed to pilot-scale evaluation
  • 7 customers successfully completed pre-commercial or commercial validation
  • Signed two additional strategic MOUs with leading South Korean cathode active material manufacturers
  • Evaluating expansion from 100 KTPA to 200 KTPA capacity
  • Target to conclude two significant binding off-take agreements later this year

NSS Subsidiary (European Operations):

  • Facing challenging operating environment in Europe
  • Elevated energy costs and subdued industrial production impacting customer demand
  • Integration progress on track with procurement, supply chain, and commercial operations coming together
  • New business head joined in June, initiated approvals with five customers across infant nutrition and dairy segments
  • Built active pipeline of 12 customer projects
  • Target for NSS to deliver similar margins as core specialty ingredients business by FY28

Management and Governance

  • Welcomed Mr. Milin Mehta to Board of Directors, bringing extensive experience in business strategy, finance, and corporate governance

Guidance and Outlook

  • Pricing actions implemented during Q1 expected to largely offset input cost impact in Q2
  • Expect specialty ingredients business to return to historical growth trajectory beginning Q2
  • Target to sustain EBITDA margins between 37% and 38%
  • Historically stronger second half performance expected due to seasonal demand patterns
  • Confident in delivering year of strong growth based on current order book and custom pipeline

Capital Structure and Asset Efficiency

  • Target asset turns between 2.7x and 3x for battery materials and greenfield facilities at scale
  • Working capital improvement target of reducing to approximately 170 days (excluding battery materials business inventory)

Geographic Performance

  • Export remains dominant revenue driver with increasing contribution
  • Europe, North America, and MENA region meaningfully contributed to growth
  • International markets carry stronger margin profile supported by differentiated and value-added products

Product Development Pipeline

  • HPMC and PVP products under development and commercial evaluation
  • Not expected to be commercialized in current financial year
  • Focus on scaling greenfield facility and bisglycinate portfolio first

Regulatory Environment

  • Recent Chinese regulatory developments (Decree No. 837) expected to increase complexity for Chinese companies seeking FEOC compliance
  • Reinforces strategic importance of credible non-China suppliers like Sudeep Advanced Materials